All In Biotech

NDA 205223 · Alembic Therap

Nuvessa

Metronidazole · Vaginal · Nitroimidazole Antimicrobial

Last checked: Nov 19, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 24, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

48,241

42,012 serious, 5,419 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2023.

NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in females 12 years of age and older. ( 1 )​

Mechanism: Metronidazole is an antimicrobial drug [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NUVESSA · METRONIDAZOLE 1.3% · GEL, VAGINAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,672
  • nausea3,469
  • off label use3,384
  • diarrhoea2,721
  • vomiting2,342
  • pyrexia2,301
  • headache2,261
  • abdominal pain2,126
  • pain2,121
  • fatigue1,960
  • dizziness1,689
  • condition aggravated1,638

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004459
2005480
2006482
2007511
2008320
2009676
2010858
20111,164
20121,431
20131,112
20141,451
20152,167
20162,469
20172,511
20184,196
20194,496
20203,830
20213,904
20223,418
20233,478
20243,179
20253,456
20262,190

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuvessa (Metronidazole)

2024 spending

$130K

Beneficiaries

439

534 claims

Per beneficiary

$295

$40.25 per unit

View as table
YearSpending
2020$58,173
2021$62,698
2022$73,522
2023$109,954
2024$129,630

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,032 on PubMed

Sponsor: Alembic Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.